Rhythm Pharmaceuticals, Inc. (RYTM) stock
Close on Nov 11, 2026Market cap $7.72BP/E –Yield –
Rhythm Pharmaceuticals, Inc. grew revenue 53.5% to $239.92M over the twelve months to Jun 30, 2026. Free cash flow was -$116.63M. At the latest close the market valued the company at $7.72B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.72B
- P/E ratio
- –
- Price to sales
- 32.19
- Price to book
- 74.99
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $239.92M
- Net income
- -$205.35M
- EPS, diluted
- -$3.11
- Free cash flow
- -$116.63M
- Book value per share
- $1.50
- Diluted shares
- 69M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $113.95
- Open
- $113.76
- Day's range
- $112.04 – $115.20
- Volume
- 740,315
- Average volume (20 days)
- 1,741,342
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.41
- 52-week range
- $74.50 – $122.20
- RSI (14 days)
- 65.5
- Volatility (1 year)
- 54.3%
- Relative volume
- 0.82×
- WACC
- 11.9%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RYTM | S&P 500 | Difference | RYTM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.6% | -2.4% | +26.0 pts | ||
| 3 months | -0.6% | -1.2% | +0.5 pts | ||
| Year to date | +4.8% | +12.3% | −7.5 pts | ||
| 1 year | +12.3% | +12.4% | −0.1 pts | ||
| 3 years | +294.1% | +78.8% | +215.3 pts | +58.0% | +21.4% |
| 5 years | +730.2% | +75.2% | +655.0 pts | +52.7% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rhythm Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Rhythm Pharmaceuticals
Pharmaceutical Preparations
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing precision medicines to treat rare neuroendocrine diseases. The company concentrates on advancing melanocortin-4 receptor agonists designed to address hyperphagia and severe obesity resulting from impaired signaling pathways in the brain. Its primary marketed therapy is IMCIVREE, which is authorized to manage weight and control hunger in adult and pediatric patients with rare conditions such as Bardet-Biedl syndrome and specific genetic deficiencies involving pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor genes. Beyond its approved treatments, the company is evaluating earlier-stage investigational drug candidates, including bivamelagon and RM-718, for hypothalamic obesity and Prader-Willi syndrome.
Company profile, executives and historyRhythm Pharmaceuticals stock: common questions
What is Rhythm Pharmaceuticals's stock price?
RYTM closed at $112.16 on Nov 11, 2026, down 1.57% on the day. Over the past 52 weeks it traded between $74.50 and $122.20.
What is Rhythm Pharmaceuticals's market cap?
Rhythm Pharmaceuticals was worth $7.72B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RYTM's P/E ratio?
Rhythm Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.11), so it has no meaningful P/E ratio.
How much revenue does Rhythm Pharmaceuticals make?
Rhythm Pharmaceuticals reported revenue of $239.92M for the twelve months to Jun 30, 2026, up 53.5% from a year earlier.
Does Rhythm Pharmaceuticals pay a dividend?
No. Rhythm Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Rhythm Pharmaceuticals report earnings next?
Rhythm Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RYTM stock performed over the past year?
Including dividends, RYTM returned +12.3% over the past year, against +12.4% for the S&P 500.
How many RYTM shares are sold short?
12M shares were sold short at the latest FINRA report, 17.14% of the float, or 23.3 days of average trading volume.
Who are Rhythm Pharmaceuticals's competitors?
Companies most similar to Rhythm Pharmaceuticals by business, industry and size include ETON, ZVRA, AMLX, PHAR, MIRM.
See a number that looks wrong?